What this page clarifies
- Reduces risk before public marketing or patient acquisition.
- Flags unsupported therapy claims and jurisdiction gaps.
- Turns regulatory uncertainty into a structured review workflow.
Questions to ask before moving forward
- Which regulator or trial registry applies?
- What can be said publicly without overclaiming?
- What evidence and adverse-event reporting is available?
Recommended pathway
- Claim and jurisdiction inventory.
- Evidence-stage label.
- Medical, legal, and communications review.